School of Medicine Publications and Presentations
Document Type
Article
Publication Date
4-3-2023
Abstract
The transcription factor Prdm16 functions as a potent suppressor of transforming growth factor-beta (TGF-β) signaling, whose inactivation is deemed essential to the progression of pancreatic ductal adenocarcinoma (PDAC). Using the KrasG12D-based mouse model of human PDAC, we surprisingly found that ablating Prdm16 did not block but instead accelerated PDAC formation and progression, suggesting that Prdm16 might function as a tumor suppressor in this malignancy. Subsequent genetic experiments showed that ablating Prdm16 along with Smad4 resulted in a shift from a well-differentiated and confined neoplasm to a highly aggressive and metastatic disease, which was associated with a striking deviation in the trajectory of the premalignant lesions. Mechanistically, we found that Smad4 interacted with and recruited Prdm16 to repress its own expression, therefore pinpointing a model in which Prdm16 functions downstream of Smad4 to constrain the PDAC malignant phenotype. Collectively, these findings unveil an unprecedented antagonistic interaction between the tumor suppressors Smad4 and Prdm16 that functions to restrict PDAC progression and metastasis.
Recommended Citation
Hurwitz, E., Parajuli, P., Ozkan, S., Prunier, C., Nguyen, T. L., Campbell, D., Friend, C., Bryan, A. A., Lu, T. X., Smith, S. C., Razzaque, M. S., Xu, K., & Atfi, A. (2023). Antagonism between Prdm16 and Smad4 specifies the trajectory and progression of pancreatic cancer. The Journal of cell biology, 222(4), e202203036. https://doi.org/10.1083/jcb.202203036
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Publication Title
The Journal of cell biology
DOI
https://doi.org/10.1083/jcb.202203036
Academic Level
faculty
Mentor/PI Department
Medical Education
Comments
© 2023 Hurwitz et al. This article is available under a Creative Commons License (Attribution 4.0 International, as described at https://creativecommons.org/licenses/by/ 4.0/).